There are currently 85 active clinical trials seeking participants for Myelodysplastic Syndromes research studies. The states with the highest number of trials for Myelodysplastic Syndromes participants are Ohio, California, New York and Texas.
Iadademstat with Hypomethylating Agent in Patients with Myelodysplastic Syndrome
NCT06502145
Recruiting
This is a phase I study with a primary objective of determining the recommended phase II dose of iadademstat with azacitidine in adult subjects with myelodysplastic syndrome (MDS).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2025
Locations: Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Myelodysplastic Syndromes
Register for Updates
Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care
NCT05745285
Recruiting
The purpose of this study is to learn about the impact that the services and programs provided by the Leukemia and Lymphoma Society have among patients with blood cancer, such as access to care, quality of life, and financial burden.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/04/2025
Locations: Sylvester Comprehensive Cancer Center, Miami, Florida +2 locations
Conditions: Leukemia, Lymphoma, Myeloma, Myelodysplastic Syndromes, Myeloproliferative Neoplasm
Register for Updates
Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment with Mylotarg, for Patients with CD33+ AML or MDS
NCT04849910
Recruiting
This is a Phase 1/2a, multicenter, open-label, first-in-human (FIH) study of VOR33 in participants with AML or MDS who are undergoing human leukocyte antigen (HLA)-matched allogeneic hematopoietic cell transplant (HCT).
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
01/30/2025
Locations: University of California San Diego Moores Cancer Center, La Jolla, California +14 locations
Conditions: Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
Register for Updates
Luspatercept and Lenalidomide (L2) in Lower-risk, Non-del(5q) MDS Patients
NCT04539236
Recruiting
The purpose of this study is to evaluate if the combination of drugs, Lenalidomide and Luspatercept, will help improve the treatment of anemia in patients with lower-risk Myelodysplastic Syndrome (MDS).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/27/2025
Locations: University of Miami, Miami, Florida +6 locations
Conditions: Myelodysplastic Syndromes
Register for Updates
First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
NCT05086315
Recruiting
This is an open-label, multicenter, Phase 1/Phase 2, dose escalation and dose expansion study to evaluate the safety, pharmacokinetics, pharmacodynamics and anti-leukemic activity of SAR443579 in various hematological malignancies.
Gender:
ALL
Ages:
1 year and above
Trial Updated:
01/23/2025
Locations: City of Hope-Site Number:8400002, Duarte, California +23 locations
Conditions: Acute Lymphocytic Leukaemia, Acute Myeloid Leukaemia Refractory, Myelodysplastic Syndromes, Blastic Plasmacytoid Dendritic Cell Neoplasia
Register for Updates
A Study of TSC-100 and TSC-101 in AML, ALL and MDS Patients Undergoing Haploidentical Donor Transplantation
NCT05473910
Recruiting
This is a multi-center, non-randomized, concurrent controlled, multi-arm, Phase 1 interventional, open-label, biologic assignment-based umbrella study evaluating the feasibility, safety and preliminary efficacy of an escalating dose regimen of up to 2 doses of TSC-100 and TSC-101 in patients with AML, MDS, or ALL following HCT from a haploidentical donor.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/22/2025
Locations: City of Hope, Duarte, California +14 locations
Conditions: AML, Myelodysplastic Syndromes, ALL, Adult
Register for Updates
Electronic Health Mindfulness-based Music Therapy Intervention for Patients Undergoing Allogeneic Stem Cell Transplantation
NCT05968963
Recruiting
The goal of this study is to pilot test an Electronic Health Mindfulness-based Music Therapy Intervention (eMBMT) intervention to improve health-related quality of life (HRQoL) and reduce symptom burden of patients undergoing allogeneic stem cell transplantation (allo-SCT).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/18/2025
Locations: University of Miami, Miami, Florida
Conditions: Stem Cell Transplantation, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Non-Hodgkin
Register for Updates
Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML
NCT05986240
Recruiting
This is a Phase 1 study investigating the safety and efficacy of Danvatirsen as a monotherapy followed by combination with Venetoclax in patients with relapsed/refractory myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). Funding Source: FDA OOPD
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/15/2025
Locations: Montefiore Medical Center, Bronx, New York +1 locations
Conditions: AML/MDS, Acute Myeloid Leukemia, Myelodysplastic Syndromes
Register for Updates
A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies
NCT05428969
Recruiting
This is a study to assess the safety of increasing dose levels of bexmarilimab when combined with standard of care (SoC) in patients with myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) or acute myeloid leukemia (AML); Phase 1 aims to identify the recommended phase 2 dose (RP2D) of bexmarilimab based on safety, tolerability and pharmacological activity; Phase 2 will investigate the preliminary efficacy of the combination treatment in selected indications from Phase 1.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/15/2025
Locations: City of Hope National Medical Center, Duarte, California +9 locations
Conditions: Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Relapsed/Refractory AML
Register for Updates
A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants
NCT06045689
Recruiting
The purpose of this study is to evaluate the efficacy and safety of Luspatercept when administered at the maximum approved dose in low-risk Myelodysplastic Syndrome participants who require red blood cell transfusions.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/10/2025
Locations: Cancer and Blood Specialty Clinic, Los Alamitos, California +63 locations
Conditions: Myelodysplastic Syndromes
Register for Updates
Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA
NCT04798339
Recruiting
This study is a multi-institution, open-label, Phase 1b/2 clinical trial evaluating the toxicity and efficacy of canakinumab in combination with darbepoetin alfa in patients with lower-risk MDS who have failed prior treatment with an Erythropoietin Stimulating Agent (ESA)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/07/2025
Locations: Moffitt Cancer Center, Tampa, Florida +1 locations
Conditions: Myelodysplastic Syndromes
Register for Updates
A Telehealth Advance Care Planning Intervention
NCT05875805
Recruiting
The objective of this project is to conduct a pilot randomized trial to assess the preliminary efficacy of a telehealth-delivered Serious Illness Care Program on healthcare communication, patient anxiety and distress, as well as completion of advance directives (specifically MOLST and healthcare proxy forms) for older patients with acute myeloid leukemia, myelodysplastic syndrome, and similar myeloid malignancies.
Gender:
ALL
Ages:
60 years and above
Trial Updated:
12/17/2024
Locations: University of Rochester, Rochester, New York
Conditions: Myeloid Malignancy, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm, Myelofibrosis
Register for Updates